Clinical Trials Logo

Clinical Trial Summary

To test whether pre - disinfection skin scrub with 4% chlorhexidine gluconate is more effective on the reduction of surgical site microbial colonization and subsequent infection than is normal saline.


Clinical Trial Description

Surgical site infections (SSIs) following elective surgical procedures occur most commonly as a result of colonization by the patient's native skin flora . The most common pathogens causing SSIs are Staphylococcus aureus and coagulase-negative Staphylococci , components of normal skin flora . Therefore, preoperative disinfection of the surgical site with an antiseptic skin preparation is standard practice before any surgical intervention to decrease skin microbial counts before incision . It is considered an important step in limiting surgical wound contamination and preventing infection.

A variety of skin-preparation agents and methods are available for preventing surgical site infections and the techniques for preoperative cleansing of the skin vary among hospitals and surgeons. There is a pressing need to elucidate the effect of cutaneous disinfection with chlorhexidine gluconate ( CHG ) in prevention of surgical site infections.

Many studies demonstrated that comparisons with cutaneous disinfection with povidone-iodine, disinfection with CHG before insertion of an intravascular device and for post-infection site care can substantially reduce the incidence of device-related infection .

Hence, this study aimed to test whether an additional chlorhexidine gluconate scrub followed by a routine disinfection would lower the incidence of surgical site culture and subsequent infection after hepatic resection. This data will show the originality and clinical importance of a cutaneous pre-disinfection scrubbing solution for such risk patients with hepatectomy. ;


Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT01782573
Study type Interventional
Source Changhua Christian Hospital
Contact
Status Completed
Phase Phase 4
Start date October 2011
Completion date September 2012

See also
  Status Clinical Trial Phase
Terminated NCT01197820 - Hepatic and Renal Thermography Using Magnetic Resonance Imaging N/A
Terminated NCT00942383 - Freehand Ultrasound Elasticity Imaging in Liver Surgery
Active, not recruiting NCT03432806 - A Study of Imaging, Blood, and Tissue Samples to Guide Treatment of Colon Cancer and Related Liver Tumors
Completed NCT01403727 - Electromagnetic Tracking of Devices During Biopsy Procedures N/A
Recruiting NCT00691691 - Stereotactic Body Radiation Therapy (SBRT) in the Treatment of Liver Tumors Phase 2
Terminated NCT00955097 - Evaluation of Intra-operative Ultrasound Contrast Enhancement in the Evaluation of Liver Tumors Phase 1
Recruiting NCT02184182 - Laparoscopic Microwave Ablation and Portal Vein Ligation for Staged Hepatectomy (LAPS) Phase 2
Completed NCT02162732 - Molecular-Guided Therapy for Childhood Cancer N/A
Recruiting NCT05990257 - CMRA for US-guided-MWA of Liver Tumors N/A
Completed NCT00828607 - Contrast Enhanced (CE) Ultrasound and CE Computed Tomography or CE Magnetic Resonance Imaging in Liver Masses N/A
Completed NCT00960609 - Communicating Veins Between Adjacent Hepatic Veins: an Intra-operative Ultrasound Study N/A
Completed NCT05445973 - Added Value of Contrast-enhanced Ultrasonography for Percutaneous Radiofrequency Ablation N/A
Completed NCT03171428 - Hepatectomy With or Without the Thoraco-abdominal Approach N/A
Completed NCT02509507 - Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Tumors Alone and in Combination With Systemic Pembrolizumab MK-3475-611/Keynote-611 Phase 1/Phase 2
Completed NCT00877136 - A Treatment of Unresectable Hepatocellular Carcinoma With TheraSphere®
Terminated NCT04315883 - Yttrium-90 (TARE-Y90) in Children, Adolescents, and Young Adults With Liver Tumors
Completed NCT01031784 - Radioactive Holmium Microspheres for the Treatment of Liver Metastases Phase 1
Active, not recruiting NCT00845689 - Prevention of Liver Damage During Liver Surgery Phase 1/Phase 2